Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770236 | 1.00 | NOD1 (0.50) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL9314969 | 1.00 | NOD1 (0.50) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| Octadecylamine SCHEMBL2156922 | 0.94 | GSR (0.54) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL4242241 | 0.94 | GSR (0.54) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL5063128 | 0.92 | EPHX2 (0.53) | FFAR4FFAR1 | |
| SCHEMBL2344189 | 0.86 | NOS1 (0.55) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL26493009 | 0.82 | GRIK1 (0.57) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL23531056 | 0.82 | GRIK1 (0.69) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL262931 | 0.82 | GRIK1 (0.69) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL3696618 | 0.82 | GRIK1 (0.69) | NOD1GRIK1GRIK2SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210236453-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | THE WILLIAM M. YARBROUGH FOUNDATION | 2021-08-05 | — | — | US | disclosed |
| US-10869855-B2 | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200206179-A1 | METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA (BPH), PROSTATITIS, AND PROSTATE CANCER | THE WILLIAM M. YARBROUGH FOUNDATION | 2020-07-02 | — | — | US | disclosed |
| US-10471039-B2 | Method for treating skin cancer | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2019-11-12 | — | — | US | disclosed |
| US-10308600-B2 | Isothiocyanate functional surfactant and associated method of use | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180289661-A1 | Method for Treating Skin Cancer | THE WILLIAM M YARBROUGH FOUNDATION | 2018-10-11 | — | — | US | disclosed |
| EP-2725907-B1 | METHOD FOR TREATING ECZEMA | THE WILLIAM M YARBROUGH FOUND (US) | 2018-09-12 | — | — | EP | disclosed |
| US-8187579-B2 | Thickening agent | AJINOMOTO CO., INC. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20090030092-A1 | THICKENING AGENT | AJINOMOTO CO., INC. (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471039-B2 | Method for treating skin cancer | MGMT, KRT18, TYR | NOD1 3248/4885GRIK1 4665/4885GRIK2 4664/4885 |
| US-10308600-B2 | Isothiocyanate functional surfactant and associated method of use | STOM, TST, SGMS1 | NOD1 266/4885GRIK1 4612/4885GRIK2 4581/4885 |
| US-20090030092-A1 | THICKENING AGENT | CUTA, NAAA, ACOT7 | NOD1 3102/4885GRIK1 2132/4885GRIK2 2675/4885 |
| US-20210236453-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | MIF, MSR1, MMP12 | NOD1 2067/4885GRIK1 3518/4885GRIK2 3719/4885 |
| US-20180289661-A1 | Method for Treating Skin Cancer | MGMT, KRT18, TYR | NOD1 3248/4885GRIK1 4665/4885GRIK2 4664/4885 |
| US-10869855-B2 | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer | BPHL, KLK3, CTH | NOD1 2262/4885GRIK1 4074/4885GRIK2 4189/4885 |
| US-20200206179-A1 | METHOD FOR TREATING BENIGN PROSTATIC HYPERPLASIA (BPH), PROSTATITIS, AND PROSTATE CANCER | BPHL, KLK3, CTH | NOD1 2262/4885GRIK1 4074/4885GRIK2 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.